Back to top
more

Eli Lilly (LLY)

(Delayed Data from NYSE)

$884.48 USD

884.48
2,454,077

-1.46 (-0.16%)

Updated Oct 1, 2024 04:00 PM ET

Pre-Market: $881.00 -3.48 (-0.39%) 9:22 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

1-Strong Buy of 5 1        

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value F Growth B Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 17% (44 out of 252)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Should You Invest in the iShares U.S. Healthcare ETF (IYH)?

by Zacks Equity Research

Sector ETF report for IYH

Should You Invest in the Health Care Select Sector SPDR ETF (XLV)?

by Zacks Equity Research

Sector ETF report for XLV

Kinjel Shah headshot

Should You Buy AbbVie Stock After Recent Parkinson's Study Success?

by Kinjel Shah

Investors who own ABBV stock may stay invested as the company has faced its biggest challenge quite well and looks set to return to robust growth next year.

Roche Ramps Up Breast Cancer Pipeline With Regor's CDK Inhibitors

by Zacks Equity Research

RHHBY has strengthened its pipeline with an agreement to acquire Regor's portfolio of next-generation CDK inhibitors for the treatment of breast cancer.

Sanofi, Regeneron's Dupixent Gets FDA Approval for COPD

by Zacks Equity Research

Sanofi and Regeneron's Dupixent becomes the first biologic treatment approved for COPD in the United States.

Bayer Reports Positive Safety Data on Parkinson's Disease Drug

by Zacks Equity Research

BAYRY's experimental Parkinson's disease drug continues to show a favorable safety profile in all 12 participants in the trial's high and low-dose cohorts at 24 months.

Is Trending Stock Eli Lilly and Company (LLY) a Buy Now?

by Zacks Equity Research

Recently, Zacks.com users have been paying close attention to Lilly (LLY). This makes it worthwhile to examine what the stock has in store.

Should Invesco Large Cap Growth ETF (PWB) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for PWB

Tracey Ryniec headshot

Stocks to Buy and Hold for 5 Years

by Tracey Ryniec

What if you fell asleep and woke up 5 years later? Would you feel confident in your stock portfolio?

Kinjel Shah headshot

Pharma Stock Roundup: JNJ's 3rd Talc-Related Bankruptcy Filing & More

by Kinjel Shah

JNJ files for voluntary bankruptcy for the third time. Pfizer withdraws sickle-cell drug drug Oxbryta from worldwide markets.

Bayer Submits Application for Label Expansion of Prostate Cancer Drug

by Zacks Equity Research

BAYRY moves ahead with the submission of an application seeking approval of darolutamide in combination with androgen deprivation therapy in patients with metastatic hormone-sensitive prostate cancer.

Eli Lilly (LLY) Stock Declines While Market Improves: Some Information for Investors

by Zacks Equity Research

Eli Lilly (LLY) closed the most recent trading day at $909.32, moving -1.65% from the previous trading session.

Kinjel Shah headshot

Buy These 5 Big Drug Stocks to Boost Your Portfolio's Health

by Kinjel Shah

Pfizer, Eli Lilly, AstraZeneca, Bayer and Sanofi can prove to be great additions to your portfolio.

Wall Street Analysts Think Lilly (LLY) Is a Good Investment: Is It?

by Zacks Equity Research

The average brokerage recommendation (ABR) for Lilly (LLY) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?

Should SPDR MSCI USA StrategicFactors ETF (QUS) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for QUS

Should You Invest in the Vanguard Health Care ETF (VHT)?

by Zacks Equity Research

Sector ETF report for VHT

Eli Lilly Secures Approval for Alzheimer's Drug Kisunla in Japan

by Zacks Equity Research

Japan is the second major market where LLY's Kisunla has been approved. The drug was first approved in the United States in July 2024.

VTYX Stock Rises on Strategic Equity Investment Deal With SNY

by Zacks Equity Research

Ventyx stock climbs 7% on signing a $27 million strategic investment agreement with Sanofi in exchange for granting exclusive rights to VTX3232.

Kinjel Shah headshot

J&J Seeks 3rd Talc-Related Bankruptcy: Time to Sell the Stock?

by Kinjel Shah

We suggest a new investor should avoid buying JNJ's stock now due to uncertainty surrounding its legal battles.

Johnson & Johnson Files for Bankruptcy Over Talc Lawsuits for the Third Time

by Zacks Equity Research

The higher settlement offer and a high percentage of claimant support may improve JNJ's chances of success after the previous two failures.

NVO Stock Down on Unsatisfactory Data From Mid-Stage Obesity Study

by Zacks Equity Research

Novo Nordisk stock falls 5.5% on unsatisfactory safety and efficacy data from a mid-stage study of investigational obesity candidate, monlunabant.

TNDM Stock Likely to Benefit From the t:slim X2-Lyumjev Offering in EU

by Zacks Equity Research

Tandem Diabetes' t:slim X2 insulin pump is now compatible with Lilly's Lyumjev in the European Union.

Kinjel Shah headshot

Pharma Stock Roundup: FDA Approvals for LLY, MRK, AZN & JNJ Drugs

by Kinjel Shah

FDA approves Lilly's eczema drug, Ebglyss, and the expanded use of Novartis' Kisqali, Merck's Keytruda and AstraZeneca's Fasenra.

Ahan Chakraborty headshot

NVO Stock Loses Around $29B in 3 Months: Buy the Dip or Steer Clear?

by Ahan Chakraborty

Despite the current downward trend of Novo Nordisk, it is an excellent stock to buy for long-term gains, driven by the stellar performance of its GLP-1 drugs.

NVO Gets Positive CHMP Opinion for Wegovy's Label Update in EU

by Zacks Equity Research

Novo Nordisk receives a positive opinion from the CHMP for a label update of Wegovy to reflect reduced heart failure symptoms and improved physical function.